The HDLBP Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma line, engineered for targeted disruption of the HDLBP gene encoding vigilin. This product provides a genetically heterogeneous pool of cells carrying loss-of-function edits across the HDLBP locus, enabling robust functional studies without clonal selection. The polyclonal format captures the averaged molecular consequences of vigilin ablation in an epithelial cancer context, making it suitable for pooled assays where population-level phenotypes, such as mRNA stabilization defects or altered cholesterol handling, are examined. By eliminating vigilin-dependent RNA regulatory networks, these cells serve as a versatile platform for dissecting post-transcriptional control mechanisms relevant to lipid metabolism and oncogenesis.
The A-549 host cell line was established from a 58-year-old male and is a widely recognized model for lung adenocarcinoma, retaining characteristic epithelial morphology and growth properties. This line is extensively applied in studies of cancer drug metabolism, respiratory virus infection, and particularly cholesterol homeostasis, given its profound sensitivity to lipid loading and statin treatment. A-549 cells express functional low-density lipoprotein receptors and exhibit active SREBP signaling, making them an optimal background for investigating the cross-talk between RNA-binding proteins and sterol regulatory networks. The combination of HDLBP knockout within this adenocarcinoma model creates a powerful system to interrogate how vigilin-mediated mRNA regulation influences tumor cell adaptation to metabolic stress.
HDLBP encodes vigilin, a highly conserved RNA-binding protein that associates with ribosomal subunits and lipid droplets, stabilizing a cohort of mRNAs central to cholesterol uptake and synthesis. Vigilin directly binds the 3′ untranslated regions (3’UTRs) of LDLR, APOB, and HMGCR transcripts, enhancing their translation and protecting them from degradation. It acts downstream of cholesterol-sensing transcription factors SREBP2 and LXR, and physically interacts with SCAP to facilitate SREBP2 trafficking to the Golgi for activation. Loss of vigilin function abrogates this stabilization, leading to reduced LDLR expression, impaired cholesterol efflux, and heightened cellular vulnerability to lipotoxicity. Moreover, vigilin interfaces with the ER stress response, linking lipid sensing to proteostasis.
In the A-549 adenocarcinoma context, HDLBP knockout establishes a disease-relevant model for studying cholesterol dysregulation in lung cancer. Tumor cells often exhibit aberrant lipid metabolism, and vigilin deletion is expected to compromise the expression of critical cholesterol import machinery, potentially sensitizing cells to statins or cholesterol deprivation. This model illuminates how RNA-binding proteins modulate the intersection of metabolic signaling and oncogenic transformation, offering insights into vulnerabilities that may be exploited therapeutically. The polyclonal nature averages over editing heterogeneity, providing reproducible, population-level insights into vigilin-dependent phenotypes, which is especially valuable for drug screening campaigns aimed at targeting cholesterol-addicted cancers.
These polyclonal knockout cells are designed for a variety of advanced research applications. They are ideal for cholesterol metabolism studies in cancer, RNA-binding protein function in tumorigenesis, and drug target discovery for metabolic diseases. Users can employ RT-qPCR to quantify LDLR and HMGCR mRNA levels, Western blotting for SREBP2 and vigilin protein abundance, cholesterol efflux assays, lipid droplet staining with BODIPY, RNA immunoprecipitation to map vigilin-mRNA interactions, polysome profiling to assess translational efficiency, and cell viability assays under lipid overload. RNA-sequencing of these cells can reveal genome-wide transcriptomic changes due to vigilin loss. For further details or technical support, please contact Ascent Research.
